John H Griffin Selected Research

Endotoxemia

11/2015	Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice.
4/2015	EPCR-dependent PAR2 activation by the blood coagulation initiation complex regulates LPS-triggered interferon responses in mice.
4/2013	Organ-specific protection against lipopolysaccharide-induced vascular leak is dependent on the endothelial protein C receptor.
4/2013	Antibody SPC-54 provides acute in vivo blockage of the murine protein C system.
9/2010	Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice.
6/2009	Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant.
10/2007	Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John H Griffin Research Topics

Disease

31	Hemorrhage 06/2023 - 04/2003
26	Ischemic Stroke 01/2022 - 09/2002
26	Thrombosis (Thrombus) 01/2021 - 06/2002
24	Inflammation (Inflammations) 04/2024 - 02/2003
22	Stroke (Strokes) 01/2022 - 07/2002
17	Venous Thrombosis (Deep-Vein Thrombosis) 02/2020 - 08/2005
17	Sepsis (Septicemia) 01/2018 - 07/2002
9	Venous Thromboembolism 01/2018 - 03/2007
8	Infarction (Infarctions) 01/2022 - 04/2003
8	Ischemia 01/2022 - 06/2003
7	Endotoxemia 11/2015 - 10/2007
6	Reperfusion Injury 01/2021 - 02/2006
4	Intracranial Hemorrhages (Intracranial Hemorrhage) 03/2024 - 11/2006
4	Wounds and Injuries (Trauma) 12/2023 - 10/2016
4	Dyslipidemias (Dyslipidemia) 01/2023 - 08/2005
4	Pulmonary Embolism 01/2021 - 09/2015
4	Hemophilia A (Haemophilia) 01/2021 - 03/2016
3	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2022 - 04/2003
3	Edema (Dropsy) 01/2022 - 04/2003
3	Infections 01/2021 - 04/2015
3	Pneumonia (Pneumonitis) 01/2018 - 09/2011
3	Lung Injury 01/2018 - 09/2011
3	Hypoxia (Hypoxemia) 01/2016 - 04/2003
3	Activated Protein C Resistance (APC Resistance) 11/2015 - 04/2007
3	Embolic Stroke 09/2012 - 09/2005
3	Atherosclerosis 11/2011 - 08/2002
3	Brain Ischemia (Cerebral Ischemia) 11/2008 - 05/2004
2	Thromboinflammation 04/2024 - 05/2020
2	Choroidal Neovascularization 06/2023 - 01/2021
2	Fibrosis (Cirrhosis) 01/2023 - 01/2022
2	Myocardial Ischemia (Ischemic Heart Diseases) 01/2021 - 01/2021
2	Bacterial Pneumonia 05/2020 - 01/2018
2	Brain Injuries (Brain Injury) 01/2019 - 04/2003
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2016 - 11/2009
2	Thromboembolism 04/2013 - 09/2009
2	Purpura Fulminans 04/2012 - 04/2007
1	Sickle Cell Anemia (Hemoglobin S Disease) 04/2024
1	Allergic Contact Dermatitis 01/2024
1	Skin Diseases (Skin Disease) 01/2024
1	Contact Dermatitis (Eczema, Contact) 01/2024
1	Heart Failure 01/2023
1	Uveitis 11/2022

Drug/Important Bio-Agent (IBA)

66	Protein CIBA 04/2024 - 06/2002
44	AnticoagulantsIBA 12/2023 - 06/2002
18	Thrombin FDA Link 04/2024 - 08/2002
13	Peptide Hydrolases (Proteases)FDA Link 04/2024 - 03/2003
13	Tissue Plasminogen Activator (Alteplase)FDA Link 03/2024 - 09/2005
12	Endothelial Protein C ReceptorIBA 01/2024 - 03/2003
10	Neuroprotective AgentsIBA 01/2022 - 04/2003
9	PAR-1 ReceptorIBA 04/2024 - 11/2006
9	Protein SIBA 01/2020 - 04/2003
8	3K3A-APC proteinIBA 01/2024 - 12/2013
7	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2004
6	Thromboplastin (Tissue Factor)IBA 10/2019 - 09/2009
5	LipopolysaccharidesIBA 11/2022 - 01/2012
5	Myosins (Myosin)IBA 01/2021 - 10/2016
5	Serine Proteases (Serine Protease)IBA 01/2020 - 12/2004
5	LipidsIBA 10/2019 - 03/2004
4	InflammasomesIBA 06/2023 - 12/2017
4	Hemostatics (Antihemorrhagics)IBA 01/2022 - 01/2021
4	Factor Xa (Coagulation Factor Xa)IBA 01/2021 - 09/2015
4	Factor VaIBA 11/2020 - 09/2002
4	Therapeutic UsesIBA 01/2018 - 09/2004
4	HDL LipoproteinsIBA 04/2012 - 08/2005
3	Hemoglobins (Hemoglobin)IBA 01/2022 - 03/2009
3	CytokinesIBA 01/2021 - 03/2018
3	Protein Isoforms (Isoforms)IBA 01/2021 - 09/2010
3	ApolipoproteinsIBA 02/2020 - 08/2005
3	lipoprotein-associated coagulation inhibitor (TFPI)IBA 01/2020 - 01/2018
3	FibrinIBA 01/2020 - 09/2009
3	CoagulantsIBA 01/2020 - 09/2005
3	ThrombomodulinIBA 01/2019 - 01/2006
3	Blood Coagulation Factors (Coagulation Factor)IBA 01/2018 - 04/2015
3	factor V LeidenIBA 11/2015 - 04/2007
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 04/2024 - 12/2018
2	Proteinase-Activated ReceptorsIBA 01/2024 - 05/2016
2	SphingolipidsIBA 01/2023 - 03/2004
2	Troponin IIBA 01/2023 - 01/2020
2	SteroidsIBA 01/2023 - 01/2019
2	FIIaIBA 01/2021 - 11/2020
2	Cardiac MyosinsIBA 01/2021 - 01/2021
2	InterferonsIBA 01/2021 - 04/2015
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 01/2020
2	NF-kappa B (NF-kB)IBA 01/2021 - 11/2006
2	AntigensIBA 01/2020 - 09/2002
2	Factor V (Coagulation Factor V)IBA 01/2016 - 04/2012
2	Biomarkers (Surrogate Marker)IBA 09/2015 - 08/2008
2	Blood Proteins (Serum Proteins)IBA 08/2013 - 05/2004
2	EndotoxinsIBA 04/2013 - 06/2009
2	oxidized low density lipoproteinIBA 09/2010 - 08/2005
2	EnzymesIBA 05/2007 - 09/2004
2	Apolipoprotein A-I (Apolipoprotein A1)IBA 03/2007 - 08/2005
1	Peptides (Polypeptides)IBA 04/2024
1	Glycerophospholipids (Phosphoglycerides)IBA 01/2023
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2023
1	Retinaldehyde (Retinal)IBA 11/2022

Therapy/Procedure

30	Therapeutics 01/2021 - 07/2002
3	Thrombectomy 01/2021 - 01/2018
3	Thrombolytic Therapy 02/2011 - 09/2005
1	General Anesthesia 04/2023